-
公开(公告)号：US07265212B2
公开(公告)日：2007-09-04
申请号：US10309764
申请日：2002-12-02
CPC分类号： C07K16/289 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56
摘要： Antibodies which specifically recognize the human CD45 isoform RB are presented. These antibodies may be used to block undesirable immune reactions in patients with transplant rejection and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and autoimmune diabetes. Preferred antibodies are fully human, monoclonal antibodies.
摘要翻译： 提出了特异性识别人CD45同种型RB的抗体。 这些抗体可用于阻止患有移植排斥和自身免疫性疾病如类风湿性关节炎，多发性硬化和自身免疫性糖尿病的患者中的不良免疫反应。 优选的抗体是完全人的单克隆抗体。
-
公开(公告)号：US20130101589A1
公开(公告)日：2013-04-25
申请号：US13607384
申请日：2012-09-07
申请人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal R. Ketchem
发明人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal R. Ketchem
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K38/00 , C07K16/2878 , C07K2317/21 , C07K2317/24 , C07K2317/73 , C07K2317/92
摘要： Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
摘要翻译： 提供多肽。 提供结合这些多肽的抗体或抗原结合结构域。 还提供了获得结合肿瘤坏死因子（TNF）相关的凋亡诱导配体（“TRAIL”）受体-2（TR-2）的抗体的方法，包括向动物施用至少一种这样的多肽并获得抗体 其结合来自动物的TR-2。 提供与TR-2反应的抗体。 还提供产生与TR-2反应的抗体的细胞，包含与TR-2反应的抗体的药物组合物，使用与TR-2反应的抗体的方法，以及包含与TR-2反应的抗体的试剂盒。 还提供了通过施用这样的多肽来降低或预防抗体与TR-2结合的方法。
-
公开(公告)号：US20090226438A1
公开(公告)日：2009-09-10
申请号：US12417438
申请日：2009-04-02
申请人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal R. Ketchem
发明人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal R. Ketchem
IPC分类号： A61K39/395 , C07K16/00 , C07K17/14 , A61K39/44
CPC分类号： A61K39/39558 , A61K38/00 , C07K16/2878 , C07K2317/21 , C07K2317/24 , C07K2317/73 , C07K2317/92
摘要： Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
摘要翻译： 提供多肽。 提供结合这些多肽的抗体或抗原结合结构域。 还提供了获得结合肿瘤坏死因子（TNF）相关的凋亡诱导配体（“TRAIL”）受体-2（TR-2）的抗体的方法，包括向动物施用至少一种这样的多肽并获得抗体 其结合来自动物的TR-2。 提供与TR-2反应的抗体。 还提供产生与TR-2反应的抗体的细胞，包含与TR-2反应的抗体的药物组合物，使用与TR-2反应的抗体的方法，以及包含与TR-2反应的抗体的试剂盒。 还提供了通过施用这样的多肽来降低或预防抗体与TR-2结合的方法。
-
公开(公告)号：US20070179086A1
公开(公告)日：2007-08-02
申请号：US11512051
申请日：2006-08-28
申请人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal Ketchem
发明人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal Ketchem
IPC分类号： A61K38/17 , C07K16/28 , C07K14/705 , C07H21/04 , C12P21/06
CPC分类号： A61K39/39558 , A61K38/00 , C07K16/2878 , C07K2317/21 , C07K2317/24 , C07K2317/73 , C07K2317/92
摘要： Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
摘要翻译： 提供多肽。 提供结合这些多肽的抗体或抗原结合结构域。 还提供了获得结合肿瘤坏死因子（TNF）相关的凋亡诱导配体（“TRAIL”）受体-2（TR-2）的抗体的方法，包括向动物施用至少一种这样的多肽并获得抗体 其结合来自动物的TR-2。 提供与TR-2反应的抗体。 还提供产生与TR-2反应的抗体的细胞，包含与TR-2反应的抗体的药物组合物，使用与TR-2反应的抗体的方法，以及包含与TR-2反应的抗体的试剂盒。 还提供了通过施用这样的多肽来降低或预防抗体与TR-2结合的方法。
-
公开(公告)号：US07521048B2
公开(公告)日：2009-04-21
申请号：US11512051
申请日：2006-08-28
申请人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal R. Ketchem
发明人： Brian Gliniak , Xiao-Dong Yang , Sharon Wong-Madden , Ian Foltz , Xiao Feng , Alison Fitch , Stephen Foster , Randal R. Ketchem
CPC分类号： A61K39/39558 , A61K38/00 , C07K16/2878 , C07K2317/21 , C07K2317/24 , C07K2317/73 , C07K2317/92
摘要： Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
摘要翻译： 提供多肽。 提供结合这些多肽的抗体或抗原结合结构域。 还提供了获得结合肿瘤坏死因子（TNF）相关的凋亡诱导配体（“TRAIL”）受体-2（TR-2）的抗体的方法，包括向动物施用至少一种这样的多肽并获得抗体 其结合来自动物的TR-2。 提供与TR-2反应的抗体。 还提供产生与TR-2反应的抗体的细胞，包含与TR-2反应的抗体的药物组合物，使用与TR-2反应的抗体的方法，以及包含与TR-2反应的抗体的试剂盒。 还提供了通过施用这样的多肽来降低或预防抗体与TR-2结合的方法。
-
公开(公告)号：US20060183887A1
公开(公告)日：2006-08-17
申请号：US11267860
申请日：2005-11-04
申请人： Aya Jakobovits , Xiao-Dong Yang , Michael Gallo , Xiao-Chi Jia
发明人： Aya Jakobovits , Xiao-Dong Yang , Michael Gallo , Xiao-Chi Jia
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/77
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.
摘要翻译： 根据本发明，提供了针对人表皮生长因子受体（EGF-r）的完全人单克隆抗体。 提供了含有重链和轻链免疫球蛋白分子的Nuclotide序列编码和氨基酸序列，特别是对应于CDR1至CDR3的连续重链和轻链序列的序列。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤。 根据本发明还提供了具有一个或多个以下功能特征的抗体：（i）抑制EGF-r的酪氨酸磷酸化，（ii）不抑制EGF-r内化，（ii）抑制EGF-r降解 ，（iii）抑制EGF诱导的EGF-r降解，（iv）保护EGF-r的苏氨酸磷酸化，（v）保护其他分子，特别是通过免疫沉淀鉴定的62KD分子的苏氨酸磷酸化，和（vi）抑制血管内皮 肿瘤细胞的细胞生长因子信号大于50％，内皮细胞相对于对照组大于40％。
-
公开(公告)号：US20060104974A1
公开(公告)日：2006-05-18
申请号：US09784950
申请日：2001-02-15
申请人： C. Davis , Russell Blacher , Jose Corvalan , Alan Culwell , Larry Green , Joanne Hales , Nancy Havrilla , Vladimir Ivanov , John Lipani , Qiang Liu , Richard Weber , Xiao-Dong Yang
发明人： C. Davis , Russell Blacher , Jose Corvalan , Alan Culwell , Larry Green , Joanne Hales , Nancy Havrilla , Vladimir Ivanov , John Lipani , Qiang Liu , Richard Weber , Xiao-Dong Yang
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2803 , A61K2039/505 , C07K14/70596 , C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.
摘要翻译： 根据本发明，我们发现在诸如T细胞，B细胞和/或单核细胞的某些细胞上表达的分子CD147可用于治疗各种疾病。 特别地，我们已经证明，结合CD147并导致这种细胞的杀伤，例如通过补体结合的抗体在治疗疾病中是有效的。 这种治疗显示有效的疾病包括但不限于：移植物抗宿主病（GVHD），器官移植排斥疾病（包括但不限于肾移植，眼部移植等），癌症（包括但不限于： 血液（即白血病和淋巴瘤），胰腺等），自身免疫疾病，炎性疾病等。
-
公开(公告)号：US06235883B1
公开(公告)日：2001-05-22
申请号：US08851362
申请日：1997-05-05
申请人： Aya Jakobovits , Xiao-Dong Yang , Michael Gallo , Xiao-Chi Jia
发明人： Aya Jakobovits , Xiao-Dong Yang , Michael Gallo , Xiao-Chi Jia
IPC分类号： C07K1628
CPC分类号： C07K16/2863 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要翻译： 根据本发明，提供了针对人表皮生长因子受体（EGF-r）的完全人单克隆抗体。 提供了含有重链和轻链免疫球蛋白分子的Nuclotide序列编码和氨基酸序列，特别是对应于CDR1至CDR3的连续重链和轻链序列的序列。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤。
-
9.发明授权公开(公告)号：US08410058B2
公开(公告)日：2013-04-02
申请号：US13078480
申请日：2011-04-01
申请人： Olivia Raeber , Gadi Gazit-Bornstein , Xiao-Dong Yang , Susan Ann Cartlidge , David William Tonge
发明人： Olivia Raeber , Gadi Gazit-Bornstein , Xiao-Dong Yang , Susan Ann Cartlidge , David William Tonge
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K16/26
CPC分类号： C07K16/22 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/30 , C07K16/303 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/09 , C12N15/11 , C12N15/63
摘要： Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.
摘要翻译： 描述了结合蛋白，例如针对IGF-II的抗体与IGF-1的交叉反应性和这种抗体的用途。 特别地，公开了针对IGF-II的完全人单克隆抗体与IGF-I的交叉反应性。 还讨论了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是来自FR1至FR4或 CDR1到CDR3。
-
公开(公告)号：US08227580B2
公开(公告)日：2012-07-24
申请号：US12767086
申请日：2010-04-26
申请人： Aya Jakobovits , Xiao-Dong Yang , Michael Gallo , Xiao-Chi Jia
发明人： Aya Jakobovits , Xiao-Dong Yang , Michael Gallo , Xiao-Chi Jia
CPC分类号： C07K16/2863 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/77
摘要： In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.
摘要翻译： 根据本发明，提供了针对人表皮生长因子受体（EGF-r）的完全人单克隆抗体。 提供了编码核酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于CDR1至CDR3的连续重链和轻链序列的序列。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤。 根据本发明还提供了具有一个或多个以下功能特征的抗体：（i）抑制EGF-r的酪氨酸磷酸化，（ii）不抑制EGF-r内化，（ii）抑制EGF-r降解 ，（iii）抑制EGF诱导的EGF-r降解，（iv）保护EGF-r的苏氨酸磷酸化，（v）保护其他分子，特别是通过免疫沉淀鉴定的62KD分子的苏氨酸磷酸化，和（vi）抑制血管内皮 肿瘤细胞的细胞生长因子信号大于50％，内皮细胞相对于对照组大于40％。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.034 秒)
